Drug Pricing Packaging Pharmaceutical Companies 
STAT
JULY 26, 2023
They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices. There are major packages on so-called PBM reform percolating in at least six different congressional committees.
STAT
OCTOBER 10, 2024
billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 21, 2022
Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).
Pharmaceutical Technology
NOVEMBER 21, 2022
Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).
Pharmaceutical Technology
JUNE 6, 2025
In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceutical companies, the insurance companies, all make money by keeping us sick. We need to fundamentally change that so that we are focusing on curing disease and making people better.”
Pharmaceutical Technology
FEBRUARY 7, 2023
An example is NICE’s Quality Adjusted Life Year score, used to price drugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Overall, it is never too soon to begin market access activities, but it can easily be too late.
BioPharma Dive
JUNE 24, 2025
Editors picks George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. 4, 2024 Permission granted by Bristol Myers Squibb Deep Dive // Brain drug revival Psychiatry drugs finally have pharma’s attention.
Expert insights. Personalized for you.
246 
Let's personalize your content